Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yervoy | Ipilimumab | First Line Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete |